Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox
Publication

Publications

Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox

Title
Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox
Type
Another Publication in an International Scientific Journal
Year
2013
Authors
costa, pz
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
soares, r
(Author)
FCNAUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Journal
Title: Life SciencesImported from Authenticus Search for Journal Publications
Vol. 92
Pages: 1037-1045
ISSN: 0024-3205
Publisher: Elsevier
Other information
Authenticus ID: P-005-01A
Abstract (EN): Diabetes mellitus (DM) is a chronic metabolic disease characterized by the presence of hyperglycemia, which can lead to many complications over time. These complications, such as nephropathy, retinopathy, neuropathy, impaired wound healing and accelerated atherosclerosis, are implicated with a large number of cellular and subcellular changes on vessels. In agreement, evidence indicates that in retinopathy, nephropathy and atherosclerotic plaque, there is excessive angiogenesis, whereas in wound healing and myocardial perfusion, blood vessel growth is impaired. Despite the awareness of this angiogenic paradox, many questions remain unanswered. This review aims at highlighting the different microvascular and macrovascular complications that are often concurrent in diabetic patients. A revision of the recent findings published in the literature regarding the angiogenic paradox will be performed. Apparently, endothelial dysfunction, as well as molecules such as vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF) play a major role in diabetic vascular complications. Specific tissues with impaired angiogenesis exhibit microenvironment features, such as increased PAI-1/uPA ratio and decreased blood flow, whereas TGFbeta increases extracellular matrix deposition, preventing the vascularization process. In addition, the monocytes/macrophages are important in endothelium activation for arteriogenesis and its arteriogenic response is reduced, leading to impaired collateral artery growth. Moreover, molecular mechanisms involved will be addressed, including abnormalities in growth factor, cytokines and metabolic derangements.
Language: English
Type (Professor's evaluation): Scientific
Contact: raqsoa@med.up.pt
No. of pages: 9
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

Schizophrenia and cancer: Is angiogenesis a missed link? (2014)
Another Publication in an International Scientific Journal
lopes, r; soares, r; figueiredo-braga, m; coelho, r
Obesity and cancer phenotype: Is angiogenesis a missed link? (2015)
Another Publication in an International Scientific Journal
Mendonca, F; soares, r
Nicotine: A pro-angiogenic factor (2009)
Another Publication in an International Scientific Journal
costa, f; soares, r
microRNAs for peripheral blood fraction identification: Origin, pathways and forensic relevance (2015)
Another Publication in an International Scientific Journal
Machado, MT; Navega, S; Dias, F; Carneiro de Sousa, MJC; Teixeira, AL; Rui Medeiros
Angiogenesis in the pathophysiology of schizophrenia - A comprehensive review and a conceptual hypothesis (2015)
Another Publication in an International Scientific Journal
Lopes, R; soares, r; Rui Coelho; Figueiredo Braga M

See all (59)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-10 at 08:23:19 | Privacy Policy | Personal Data Protection Policy | Whistleblowing